Entyvio superior to Humira in moderate, severe ulcerative colitis

Entyvio conferred superior clinical remission and mucosal healing compared with Humira among patients with moderately to severely active ulcerative colitis, according to results of a phase 3b randomized trial presented at the Congress of the European Crohn’s and Colitis Organisation.
“With multiple agents available for treating ulcerative colitis, particularly the newer agents such as the biologic therapies, it is sometimes difficult to decide which treatment you should use and in what order,” Bruce E. Sands, MD, MS, chief of the Dr. Henry D. Janowitz Division of

Source link

Related posts

Veterans Health Administration Hospitals Outperform Non-VHAs


Early Detection of Pancreatic Cancer: Opportunities and Challenges


Alcohol Consumption Per Capita Increasing Among Adults


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy